| scholarly article | Q13442814 |
| P50 | author | April M Young | Q57097572 |
| Jennifer R. Havens | Q39768887 | ||
| P2093 | author name string | Carl G Leukefeld | |
| Carrie B Oser | |||
| Richard A Crosby | |||
| Dustin B Stephens | |||
| P2860 | cites work | The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis | Q21563395 |
| Clinical significance of hepatitis C virus genotypes | Q24514512 | ||
| Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 | ||
| Detection of hepatitis C virus in the nasal secretions of an intranasal drug-user | Q24792631 | ||
| A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades | Q27473000 | ||
| Never injected, but hepatitis C virus-infected: a study among self-declared never-injecting drug users from the Amsterdam Cohort Studies | Q27489900 | ||
| Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection | Q27490862 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Hepatocellular carcinoma in cirrhosis: incidence and risk factors | Q28290048 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| The HCV Synthesis Project: scope, methodology, and preliminary results | Q33369233 | ||
| Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study | Q33374135 | ||
| Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population | Q33617717 | ||
| Hepatitis C: natural history, diagnosis, and management. | Q33655805 | ||
| Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection | Q33853655 | ||
| Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004-2005. | Q43046712 | ||
| The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users | Q43047743 | ||
| Hepatitis C virus genotype 1b, cirrhosis, and risk of hepatocellular carcinoma. | Q43047932 | ||
| Molecular epidemiology of a hepatitis C virus outbreak in a hemodialysis unit in Italy | Q43048049 | ||
| Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage | Q43048565 | ||
| A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users | Q44109037 | ||
| Direct economic burden of chronic hepatitis C virus in a United States managed care population | Q44154823 | ||
| Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population | Q44324155 | ||
| Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System | Q45332329 | ||
| Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations | Q45363548 | ||
| The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs | Q45374021 | ||
| Trends in health care resource use for hepatitis C virus infection in the United States | Q45422078 | ||
| Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. | Q45423068 | ||
| Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I | Q45752944 | ||
| Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis | Q45758628 | ||
| Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users | Q45767660 | ||
| Risk factors for the rising rates of primary liver cancer in the United States | Q48624193 | ||
| Interferon alfacon-1: a novel interferon for the treatment of chronic hepatitis C. | Q50569785 | ||
| Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. | Q50572139 | ||
| Respondent-Driven Sampling: A New Approach to the Study of Hidden Populations | Q56505048 | ||
| Respondent-Driven Sampling II: Deriving Valid Population Estimates from Chain-Referral Samples of Hidden Populations | Q56505051 | ||
| A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C | Q60920135 | ||
| Effects of hepatitis C and B viruses infection on the development of hepatocellular carcinoma | Q71663948 | ||
| Hepatitis C virus and hepatocellular carcinoma | Q73401240 | ||
| Sharing of drug preparation equipment as a risk factor for hepatitis C | Q73466639 | ||
| Hepatitis C and hepatocellular carcinoma | Q73717368 | ||
| Management of hepatitis C | Q74147544 | ||
| NIH Consensus Statement on Management of Hepatitis C: 2002 | Q75442808 | ||
| Natural history of hepatitis C | Q80384219 | ||
| Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. | Q33865320 | ||
| The epidemic behavior of the hepatitis C virus | Q33952875 | ||
| The natural history of hepatitis C virus infection: host, viral, and environmental factors | Q33974693 | ||
| Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. | Q34083431 | ||
| Telaprevir for previously treated chronic HCV infection | Q34109057 | ||
| Protection against persistence of hepatitis C. | Q34126534 | ||
| Hepatitis C treatment: current and future perspectives | Q34147323 | ||
| Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. | Q34258184 | ||
| Update: syringe exchange programs--United States, 2002. | Q34433702 | ||
| Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. | Q34517293 | ||
| Doing harm reduction better: syringe exchange in the United States | Q34944380 | ||
| Surveillance for acute viral hepatitis - United States, 2007. | Q34983660 | ||
| Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users | Q35501675 | ||
| Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. | Q35683199 | ||
| Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation | Q35907209 | ||
| Hepatitis C virus genotypes in Korea and their relationship to clinical outcome in type C chronic liver diseases | Q35938587 | ||
| Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the "real-life setting" proves the concept | Q35959954 | ||
| Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users | Q36088744 | ||
| Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women | Q36384812 | ||
| Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. | Q36754880 | ||
| Hepatitis C treatment for injection drug users: a review of the available evidence | Q37546106 | ||
| Review of consensus interferon in the treatment of chronic hepatitis C. | Q37586950 | ||
| Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. | Q37772959 | ||
| The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients | Q37825956 | ||
| Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations | Q37922339 | ||
| Future of hepatitis C therapy: development of direct-acting antivirals | Q37928362 | ||
| Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review | Q37945954 | ||
| Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection | Q37966627 | ||
| Spread times of hepatitis C virus estimated by the molecular clock differ among Japan, the United States and Egypt in reflection of their distinct socioeconomic backgrounds | Q39256071 | ||
| Lack of association between genotypes and subtypes of HCV and occurrence of hepatocellular carcinoma in Egypt | Q39416212 | ||
| Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started | Q39446797 | ||
| Hepatocellular carcinoma in Sweden: its association with viral hepatitis, especially with hepatitis C viral genotypes | Q39537853 | ||
| Respondent-driven sampling in the recruitment of illicit stimulant drug users in a rural setting: findings and technical issues | Q39765276 | ||
| Differences in prevalence of prescription opiate misuse among rural and urban probationers | Q39797011 | ||
| Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. | Q39808476 | ||
| Humanistic and economic impacts of hepatitis C infection in the United States | Q39815361 | ||
| Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. | Q39820916 | ||
| Should active injecting drug users receive treatment for chronic hepatitis C? | Q39961988 | ||
| A comparison of rural and urban nonmedical prescription opioid users' lifetime and recent drug use. | Q40014338 | ||
| Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States | Q40300556 | ||
| Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium | Q40411156 | ||
| Correlation between histologic staging, hepatitis C virus genotypes and clinical features in HCV chronic hepatitis: evidence of a new pattern | Q40570951 | ||
| Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients | Q42671117 | ||
| Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study | Q42882392 | ||
| Changing HCV genotypes distribution in Poland--relation to source and time of infection. | Q42977287 | ||
| The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses | Q42977314 | ||
| Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection | Q42977637 | ||
| Risk factors for the transmission of hepatitis C. | Q42979048 | ||
| Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group | Q42979181 | ||
| Lack of association between type of hepatitis C virus, serum load and severity of liver disease | Q42979378 | ||
| High prevalence of hepatitis C virus (HCV) genotype 2 in Italian patients with chronic liver disease. | Q42981384 | ||
| Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study | Q42981575 | ||
| Hepatitis C virus 1b, cirrhosis, and hepatocellular carcinoma | Q42981585 | ||
| HCV genotypes in patients with liver disease of different stages and severity | Q42983650 | ||
| High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection | Q42985356 | ||
| Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma | Q42986448 | ||
| Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. | Q42986862 | ||
| Characteristics of patients with chronic infection due to hepatitis C virus of mixed subtype: prevalence, viral RNA concentrations, and response to interferon therapy | Q42986905 | ||
| Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis | Q42987117 | ||
| Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan | Q42988039 | ||
| Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters | Q42988172 | ||
| Relationship of hepatitis C virus genotypes and viremia levels with development of hepatocellular carcinoma among Japanese | Q42990403 | ||
| Changes in modes of hepatitis C infection acquisition and genotypes in southwest China | Q42990679 | ||
| Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs | Q42991529 | ||
| Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: Full-length sequences of two new subtype 6w strains and a recombinant form_2b6w | Q42993100 | ||
| Hepatitis C virus recombinants are rare even among intravenous drug users. | Q42993722 | ||
| Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States | Q42993836 | ||
| Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance | Q42994848 | ||
| Molecular epidemiology of hepatitis C virus genotypes in west Mexico | Q42995874 | ||
| Hepatitis C virus load and survival among injection drug users in the United States | Q42996922 | ||
| Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma | Q42996959 | ||
| Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. | Q42997217 | ||
| Reinfection with hepatitis C virus following sustained virological response in injection drug users | Q42998179 | ||
| Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States | Q42998939 | ||
| Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C | Q42999976 | ||
| Diversity of hepatitis C virus genotypes among intravenous heroin users in Taiwan | Q43000397 | ||
| Hepatitis C virus reinfection in injection drug users | Q43032645 | ||
| The role of triple therapy in HCV genotype 1-experienced patients | Q43032735 | ||
| The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending | Q43033546 | ||
| Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study | Q43039760 | ||
| P433 | issue | 9 | |
| P921 | main subject | Appalachia | Q2673740 |
| P304 | page(s) | 1376-1387 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Journal of Medical Virology | Q15716684 |
| P1476 | title | Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia | |
| P478 | volume | 84 |
| Q38995692 | Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype |
| Q30209037 | Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. |
| Q41026046 | Epidemiology of Acute Hepatitis B in the United States From Population-Based Surveillance, 2006-2011. |
| Q35751678 | Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission |
| Q38071386 | How to optimize HCV therapy in genotype 2 patients |
| Q38174243 | How to optimize current treatment of genotype 2 hepatitis C virus infection |
| Q36698904 | Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status. |
| Q40112691 | Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs |
| Q36312926 | Social networks and HCV viraemia in anti-HCV-positive rural drug users. |
Search more.